5-APDB

5-APDB
Clinical data
Other names	5-(2-Aminopropyl)-2,3-dihydrobenzofuran; 3-Desoxy-MDA; EMA-4; BF5AP
Routes of; administration	Oral
Drug class	Entactogen; Serotonin releasing agent; Serotonin receptor modulator
ATC code	None;
Legal status
Legal status	BR: Class F2 (Prohibited psychotropics); CA: Schedule I; DE: NpSG (Industrial and scientific use only); UK: Class B;
Identifiers
	IUPAC name 1-(2,3-dihydro-1-benzofuran-5-yl)propan-2-amine;
CAS Number	152624-03-8 ;
PubChem CID	192601;
ChemSpider	167143 ;
UNII	UI10BAJ8SH;
CompTox Dashboard (EPA)	DTXSID70934560 ;
Chemical and physical data
Formula	C11H15NO
Molar mass	177.247 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(CC1=CC2=C(C=C1)OCC2)N;
	InChI InChI=1S/C11H15NO/c1-8(12)6-9-2-3-11-10(7-9)4-5-13-11/h2-3,7-8H,4-6,12H2,1H3 ; Key:PZTJXZKNTPCPJL-UHFFFAOYSA-N ;
	(what is this?) (verify)

5-APDB, also known as 5-(2-aminopropyl)-2,3-dihydrobenzofuran or as 3-desoxy-MDA, is an entactogen of the phenethylamine, amphetamine, and dihydrobenzofuran families. It is an analogue of MDA where the heterocyclic 3-position oxygen from the 3,4-methylenedioxy ring has been replaced by a methylene bridge. 6-APDB is an analogue of 5-APDB where the 4-position oxygen has been replaced by a methylene bridge instead. 5-APDB was developed by a team led by David E. Nichols at Purdue University as part of their research into non-neurotoxic analogues of MDMA and first described in 1993.